Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1210/jc.2019-00677 | Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial |
| https://doi.org/10.1097/gme.0000000000001510 | A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause |
| https://doi.org/10.1126/scisignal.aal0180 | A natural ligand for the orphan receptor GPR15 modulates lymphocyte recruitment to epithelia |
| https://doi.org/10.1097/gme.0000000000001621 | Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA) |
| https://doi.org/10.1093/toxsci/kfy213 | Assessment of a Urinary Kidney MicroRNA Panel as Potential Nephron Segment-Specific Biomarkers of Subacute Renal Toxicity in Preclinical Rat Models |
| https://doi.org/10.1016/j.maturitas.2017.06.007 | Clinical evaluation of the NK3 receptor antagonist fezolinetant (a.k.a. ESN364) for the treatment of menopausal hot flashes |
| https://doi.org/10.3389/fonc.2019.01253 | Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis |
| https://doi.org/10.1093/toxsci/kfy204 | Fatty-Acid Binding Protein 4 (FABP4) as a Potential Preclinical Biomarker of Drug-Induced Kidney Injury |
| https://doi.org/10.1210/js.2019-or33-6 | OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study |
| https://doi.org/10.1016/j.maturitas.2019.04.081 | The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: a randomized, placebo-controlled, double-blind, dose-ranging study |
| https://doi.org/10.1002/9781119092599.ch19 | Optimization of a Macrocyclic Ghrelin Receptor Agonist (Part II) |
| https://doi.org/10.3389/fonc.2020.00977 | Corrigendum: Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis |
| https://doi.org/10.1212/wnl.90.15_supplement.s32.003 | In Vitro Characterization of Agonist Binding and Functional Activity at a Panel of Serotonin Receptor Subtypes for Lasmiditan, Triptans and Other 5-HT Receptor Ligands and Activity Relationships for Contraction of Human Isolated Coronary Artery (S32.003) |
| https://doi.org/10.1002/cpdd.1613 | Concentration–QTc Modeling to Support Clinical Development of Fezolinetant |
| https://doi.org/10.1007/s13318-026-00995-2 | Clinical Pharmacokinetics, Mass Balance and Metabolism of Fezolinetant in Postmenopausal Women |